🇺🇸 FDA
Patent

US 7659278

Use of low molecular weight compounds for preparing a medicament useful in treating mutant p53 mediated diseases

granted A61KA61K31/4015A61K31/439

Quick answer

US patent 7659278 (Use of low molecular weight compounds for preparing a medicament useful in treating mutant p53 mediated diseases) held by APREA AB expires Mon Feb 04 2030 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
APREA AB
Grant date
Tue Feb 09 2010 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Feb 04 2030 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
2
CPC classes
A61K, A61K31/4015, A61K31/439, A61K31/4745, A61K31/519